Hi Tech Pharmacal (HITK) 10-Q 10 Dec 13 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Oct. 31, 2013	Dec. 06, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Oct-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'HITK	'
Entity Registrant Name	'HI TECH PHARMACAL CO INC	'
Entity Central Index Key	'0000887497	'
Current Fiscal Year End Date	'--04-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	13,853,000

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Oct. 31, 2013	Apr. 30, 2013
CURRENT ASSETS:	'	'
Cash and cash equivalents	$108,838,000	$100,610,000
Accounts receivable, less allowances	69,016,000	63,775,000
Inventory	45,879,000	39,229,000
Prepaid income taxes	1,043,000	'
Deferred income taxes	13,381,000	12,321,000
Other current assets	3,227,000	3,622,000
TOTAL CURRENT ASSETS	241,384,000	219,557,000
Property and equipment - net	35,011,000	32,168,000
Intangible assets - net	39,979,000	40,887,000
Deferred income taxes	2,503,000	1,956,000
Other assets	308,000	428,000
TOTAL ASSETS	319,185,000	294,996,000
CURRENT LIABILITIES:	'	'
Accounts payable	13,508,000	9,768,000
Accrued expenses	13,646,000	13,637,000
Accrued legal settlements	26,400,000	16,200,000
Current portion of long-term debt	'	355,000
Current portion of contingent payment liability	2,875,000	2,875,000
Taxes payable	'	1,061,000
TOTAL CURRENT LIABILITIES	56,429,000	43,896,000
Contingent payment liability, net of current portion	3,570,000	4,844,000
Long-term debt, net of current portion	'	888,000
TOTAL LIABILITIES	59,999,000	49,628,000
Commitments and Contingencies (Note 14)	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred stock, par value $.01 per share; authorized 3,000,000 shares, none issued	'	'
Common stock, par value $.01 per share; authorized 50,000,000 shares, issued 16,358,000 at October 31, 2013 and 16,067,000 at April 30, 2013, respectively	164,000	161,000
Additional paid-in capital	110,405,000	101,203,000
Retained earnings	174,042,000	168,305,000
Treasury stock, 2,517,000 and 2,491,000 shares of common stock, at cost on October 31, 2013 and April 30, 2013, respectively	-25,425,000	-24,301,000
TOTAL STOCKHOLDERS' EQUITY	259,186,000	245,368,000
LIABILITIES AND STOCKHOLDERS' EQUITY	$319,185,000	$294,996,000

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	16,358,000	16,067,000
Treasury stock, shares	2,517,000	2,491,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Income Statement [Abstract]	'	'	'	'
NET SALES	$58,601,000	$57,537,000	$109,102,000	$109,580,000
Cost of goods sold	27,291,000	27,948,000	52,367,000	54,670,000
GROSS PROFIT	31,310,000	29,589,000	56,735,000	54,910,000
COST AND EXPENSES:	'	'	'	'
Selling, general and administrative expenses	13,607,000	11,706,000	26,549,000	22,337,000
Amortization expense	1,651,000	1,761,000	3,309,000	3,518,000
Research and product development costs	5,091,000	3,343,000	9,050,000	7,815,000
Royalty income	-276,000	-400,000	-570,000	-1,035,000
Contract research income	-55,000	-2,000	-554,000	-2,000
Settlements and loss contingencies	9,500,000	'	10,200,000	'
Interest expense	69,000	147,000	176,000	303,000
Interest income and other	-52,000	-77,000	-90,000	-123,000
TOTAL	29,535,000	16,478,000	48,070,000	32,813,000
Income before income tax expense	1,775,000	13,111,000	8,665,000	22,097,000
Income tax expense	588,000	4,187,000	2,928,000	7,169,000
NET INCOME	$1,187,000	$8,924,000	$5,737,000	$14,928,000
BASIC INCOME PER SHARE	$0.09	$0.67	$0.42	$1.13
DILUTED INCOME PER SHARE	$0.08	$0.66	$0.41	$1.10
Weighted average common shares outstanding - basic	13,690,000	13,238,000	13,635,000	13,154,000
Effect of potential common shares	376,000	346,000	420,000	419,000
Weighted average common shares outstanding - diluted	14,066,000	13,584,000	14,055,000	13,573,000

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
NET INCOME	$1,187,000	$8,924,000	$5,737,000	$14,928,000
Other comprehensive income, net of tax	'	'	'	'
TOTAL COMPREHENSIVE INCOME	$1,187,000	$8,924,000	$5,737,000	$14,928,000

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Statement Of Cash Flows [Abstract]	'	'
NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES	$12,902,000	$14,479,000
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of property, plant and equipment	-5,142,000	-2,467,000
Purchase of intangible assets	-2,475,000	-100,000
Proceeds from sale of intangible assets	74,000	'
Payment of contingent liability	-1,274,000	-1,203,000
NET CASH (USED IN) INVESTING ACTIVITIES	-8,817,000	-3,770,000
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Issuance of common stock on exercise of options	4,099,000	4,408,000
Tax benefits of stock incentives	1,287,000	1,604,000
Payments of long-term debt	-1,243,000	-177,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,143,000	5,835,000
NET INCREASE IN CASH AND CASH EQUIVALENTS	8,228,000	16,544,000
Cash and cash equivalents at beginning of the period	100,610,000	87,549,000
CASH AND CASH EQUIVALENTS AT END OF PERIOD	108,838,000	104,093,000
Supplemental disclosures of cash flow information:	'	'
Interest paid	176,000	303,000
Income taxes paid	5,250,000	500,000
Non-cash financing transaction:	'	'
Surrender of common stock as exercise price for options	$1,124,000	'

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1. BASIS OF PRESENTATION:
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The preparation of the Company’s financial statements in conformity with US GAAP necessarily requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the balance sheet dates and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates and assumptions. Operating results for the three and six month periods ended October 31, 2013 are not necessarily indicative of the results that may be expected for the year ending April 30, 2014. For further information, refer to the consolidated financial statements and footnotes thereto for the year ended April 30, 2013 in the Company’s Annual Report on Form 10-K.

Business

Business	6 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Business	'
	2. BUSINESS:
	Hi-Tech Pharmacal Co., Inc. (“Hi-Tech” or the “Company”, which may be referred to as “we”, “us” or “our”), a Delaware corporation, incorporated in April 1982, is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and over-the-counter (“OTC”) products. The Company specializes in the manufacture of liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company’s Health Care Products (“HCP”) division is a developer and marketer of branded prescription and OTC products for the diabetes marketplace. Hi-Tech’s ECR Pharmaceuticals (“ECR”) subsidiary markets branded prescription products.
	On August 26, 2013, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Akorn, Inc., a Louisiana corporation (“Parent”) and Akorn Enterprises, Inc. (“Purchaser”), a Delaware corporation and wholly owned subsidiary of Parent. The Merger Agreement provides for the merger of Purchaser with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”). Subject to the terms and conditions of the Merger Agreement, upon completion of the Merger, each share of our common stock, par value $0.01 (each a “Share”) issued and outstanding immediately prior to such time, other than our treasury shares and our shares of common stock, owned by Parent of Purchaser or any other of our or Parent’s wholly-owned subsidiaries (each of which will be cancelled), and other than shares of common stock as to which dissenters’ rights have been properly exercised, shall be cancelled and converted into the right to receive $43.50 in cash (the “Merger Consideration”), without interest, less any applicable withholding taxes, upon surrender of the outstanding Shares. In addition, each outstanding option, restricted stock grant, restricted stock subject to vesting or similar rights to purchase or acquire Shares (“Stock Rights”), whether or not vested, will be cancelled in exchange for the right to receive a cash payment equal to the Merger Consideration, less the applicable exercise price of such Stock Right, if any.
	We expect the Merger to close in the first quarter of 2014. Some of the conditions to closing include:
		•	the expiration or termination of the applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”), as amended;
		•	certain materiality exceptions, the accuracy of the representations and warranties made by us, Parent and Purchaser, respectively;
		•	compliance in all material respects by us, Parent and Purchaser with each of our respective obligations under the Merger Agreement;
		•	the absence of any change or effect that, individually or in the aggregate, has had a Material Adverse Effect or Purchaser Material Adverse Effect (as such terms are defined in the Merger Agreement);
		•	the absence of any order, injunction or decree or any statute, rule or regulation that prohibits or makes illegal the consummation of the Merger; and
		•	the adoption of the Merger Agreement by the affirmative vote of the holders of the requisite number of shares of capital stock of the Company in accordance with the Company’s Certificate of Incorporation, the Delaware General Corporation Law, and all other applicable law.
	The Merger Agreement contains termination rights for us, Purchaser and Parent. The Merger Agreement provides that Parent will be required to pay us a termination fee of $41,639,000 if, on or prior to April 26 2014, (i) the Merger Agreement is terminated by us as a result of a Financing Failure (as defined in the Merger Agreement) or (ii) the Merger Agreement is terminated as a result of a failure to obtain regulatory approval or clearance with respect to the HSR Act or other applicable antitrust laws. If the Merger Agreement is terminated after April 26, 2014, for either of these reasons, Parent will be required to pay the Company a termination fee of $48,045,000.
	The Merger Agreement also provides that we will be required to pay the Parent a termination fee of $20,819,000 under certain circumstances, including if (i) we terminate the Merger Agreement due to the receipt of a superior proposal or the Parent or Purchaser terminates the Merger Agreement due to a Change of Recommendation; provided however, if Parent or Purchaser terminates the Merger Agreement, or our stockholders fail to approve the Merger, as a result of a Change of Recommendation (as defined in the Merger Agreement) related to an Intervening Event (as defined in the Merger Agreement), we will be required to pay a termination fee of $32,030,000 or (ii) (a) the Merger Agreement is terminated because our stockholders fail to approve the Merger or because of certain of breaches by us of the Merger Agreement, (b) a third party publicly discloses or makes known to the Board of Directors a bona fide alternative acquisition proposal prior to such termination and (c) we enter into or consummate an alternative acquisition agreement within 12 months of the termination of the Merger Agreement.
	For more information about the Merger and the Agreement, please see our Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 27, 2013, our Definitive Proxy Statement on Schedule 14A filed on November 7, 2013 and our Proxy Statement Supplement filed on November 27, 2013.
	On August 26, 2013, our Board of Directors approved an amendment to, and restatement of, our Bylaws, effective as of such date, to include a new Article XII of the Bylaws which provides that unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or (iv) any action asserting a claim governed by the internal affairs doctrine shall be a state or federal court located within the State of Delaware, in all cases subject to such court having personal jurisdiction over the indispensable parties named as defendants. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions of Article XII.

Revenue_Recognition

Revenue Recognition	6 Months Ended
	Oct. 31, 2013
Text Block [Abstract]	'
Revenue Recognition	'
	3. REVENUE RECOGNITION:
	Revenue is recognized for product sales upon shipment and passing of title and risk of loss to the customer and when estimates of discounts, rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments are reasonably determinable, collection is reasonably assured and the Company has no further performance obligations. These estimates are presented in the financial statements as reductions to net revenues and accounts receivable. Contract research income is recognized as work is completed and as billable costs are incurred. In certain cases, contract research income is based on attainment of designated milestones. Advance payments may be received to fund certain development costs.
	Royalty income is related to sales of divested products which are sold by third parties. For those agreements, the Company recognizes revenue based on royalties reported by those third parties and earned during the applicable period.

Net_Income_Per_Share

Net Income Per Share	6 Months Ended
	Oct. 31, 2013
Earnings Per Share [Abstract]	'
Net Income Per Share	'
	4. NET INCOME PER SHARE:
	Basic net income per common share is computed based on the weighted average number of common shares outstanding and on the weighted average number of common shares and share equivalents (stock options) outstanding for diluted earnings per share. The weighted average number of shares outstanding used in the computation of diluted net earnings per share does not include the effect of potentially outstanding common stock whose effect would have been antidilutive. Such outstanding potential shares consisted of options totaling 0 and 40,000 shares for the three and six months ended October 31, 2013 and 2012, respectively.

Accounts_Receivable

Accounts Receivable	6 Months Ended
	Oct. 31, 2013
Receivables [Abstract]	'
Accounts Receivable	'
	5. ACCOUNTS RECEIVABLE:
	We recognize revenue for product sales when title and risk of loss have transferred to our customers, when reliable estimates of rebates, chargebacks, returns and other adjustments can be made, and when collectability is reasonably assured. This is generally at the time that products are received by our direct customers. Upon recognizing revenue from a sale, we record estimates for chargebacks, rebates and incentive programs, product returns, cash discounts and other sales reserves that reduce accounts receivable.
	At October 31, 2013 and April 30, 2013, accounts receivable balances, net of returns and allowances and allowance for doubtful accounts, are as follows:
			October 31, 2013			April 30, 2013
	Accounts receivable, gross		$	93,310,000		$	86,457,000
	Adjustment for returns and price allowances (a)			(23,794,000	)		(22,182,000	)
	Allowance for doubtful accounts			(500,000	)		(500,000	)
	Accounts receivable, net		$	69,016,000		$	63,775,000
	(a)	directly reduces gross revenue
	Our product revenues are typically subject to agreements with customers allowing chargebacks, rebates, rights of returns, pricing adjustments and other allowances. Based on our agreements and contracts with our customers, we calculate adjustments for these items when we recognize revenue and we book the adjustments against accounts receivable and revenue. Chargebacks, primarily from wholesalers, are the most significant of these items. Chargebacks result from arrangements we have with end users establishing prices for products for which the end user independently selects a wholesaler from which to purchase. A chargeback represents the difference between our invoice price to the wholesaler, which is typically stated at wholesale acquisition cost, and the end customer’s contract price, which is lower. We credit the wholesaler for purchases by end customers at the lower price. Therefore, we record these chargebacks at the time we recognize revenue in connection with our sales to wholesalers.
	The reserve for chargebacks is computed in the following manner. The Company obtains wholesaler inventory data for the wholesalers which represent approximately 95% of our chargeback activity. This inventory is multiplied by the historical percentage of units that are charged back and by the price adjustment per unit to arrive at the chargeback accrual. This calculation is performed by product by customer. The calculated amount of chargebacks could be affected by other factors such as:
		•		a change in retail customer mix
		•		a change in negotiated terms with retailers
		•		product sales mix at the wholesaler
		•		retail inventory levels
		•		changes in Wholesale Acquisition Cost (“WAC”)
	The Company continually monitors the chargeback activity and adjusts the provisions for chargebacks when we believe that the actual chargebacks will differ from our original provisions.
	Consistent with industry practice, the Company maintains a return policy that allows our customers to return product within a specified period. The Company’s estimate for returns is based upon its historical experience with actual returns. The Company continually monitors its estimates for returns and makes adjustments when it believes that actual product returns may differ from the established accruals.
	Included in the adjustment for sales allowances and returns is a reserve for credits taken by our customers for rebates, return authorizations and other discounts.
	Sales discounts are granted for prompt payment. The reserve for sales discounts is based on invoices outstanding and assumes that 100% of available discounts will be taken.
	Price adjustments, including shelf stock adjustments, are credits issued from time to time to reflect decreases in the selling prices of our products which our customer has remaining in its inventory at the time of the price reduction. Decreases in our selling prices are discretionary decisions made by us to reflect market conditions. Amounts recorded for estimated price adjustments are based upon specified terms with direct customers, estimated launch dates of competing products, estimated declines in market price and inventory held by the customer. The Company analyzes this on a case by case basis and makes adjustments to reserves as necessary.
	The Company adequately reserves for chargebacks, discounts, allowances and returns in the period in which the sales take place. No material amounts included in the provision for chargebacks and the provision for sales discounts recorded in the current period relate to sales made in the prior periods. The provision for sales allowances and returns includes reserves for items sold in the current and prior periods. The Company has substantially and consistently used the same estimating methods. We have refined the methods as new data became available. There have been no material differences between the estimates applied and actual results.
	The following table presents the roll forward of each significant estimate as of October 31, 2013 and October 31, 2012 and for the six months then ended, respectively.
	For the six months ended October 31, 2013		Beginning			Current			Actual Credits			Ending
			Balance			Provision			in Current			Balance
			May 1						Period			October 31
	Chargebacks		$	13,357,000		$	88,374,000		$	(88,313,000	)	$	13,418,000
	Sales discounts			1,950,000			4,910,000			(4,809,000	)		2,051,000
	Sales allowances & returns			6,875,000			24,836,000			(23,386,000	)		8,325,000
	Total adjustment for returns & price allowances		$	22,182,000		$	118,120,000		$	(116,508,000	)	$	23,794,000
	For the six months ended October 31, 2012
	Chargebacks		$	10,477,000		$	70,222,000		$	(70,458,000	)	$	10,241,000
	Sales discounts			1,813,000			4,555,000			(4,214,000	)		2,154,000
	Sales allowances & returns			5,745,000			25,516,000			(22,307,000	)		8,954,000
	Total adjustment for returns & price allowances		$	18,035,000		$	100,293,000		$	(96,979,000	)	$	21,349,000

Inventory

Inventory	6 Months Ended
	Oct. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory	'
	6. INVENTORY:
	The components of inventory consist of the following:
		October 31,		April 30,
		2013		2013
	Finished goods	$	18,285,000	$	14,575,000
	Work in process		311,000		352,000
	Raw materials		27,283,000		24,302,000
	Total inventory	$	45,879,000	$	39,229,000

Property_and_Equipment

Property and Equipment	6 Months Ended
	Oct. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	7. PROPERTY AND EQUIPMENT:
	The components of property and equipment consist of the following:
		October 31,		April 30,
		2013		2013
	Land and building and improvements	$	21,989,000	$	21,592,000
	Machinery and equipment		39,150,000		35,145,000
	Transportation equipment		69,000		69,000
	Computer equipment and systems		7,567,000		6,866,000
	Furniture and fixtures		1,352,000		1,313,000
		$	70,127,000	$	64,985,000
	Accumulated depreciation and amortization		35,116,000		32,817,000
	Total property and equipment	$	35,011,000	$	32,168,000
	The Company incurred depreciation expense of $2,299,000 and $1,936,000 for the six months ended October 31, 2013 and 2012, respectively. Depreciation expense for the three months ended October 31, 2013 and 2012 was $1,163,000 and $1,007,000, respectively. No depreciation is taken on land with a carrying value of $1,860,000 at October 31, 2013 and April 30, 2013.

Intangible_Assets

Intangible Assets	6 Months Ended
	Oct. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	8. INTANGIBLE ASSETS:
	The components of net intangible assets are as follows:
			October 31, 2013					April 30, 2013
			Gross Carrying		Accumulated			Gross Carrying		Accumulated			Amortization Period
			Amount		Amortization			Amount		Amortization
	TussiCaps® intangible assets		$	22,126,000	$	(6,474,000	)	$	22,126,000	$	(4,980,000	)		5-10 years
	ECR intangible assets (a)			7,334,000		(2,917,000	)		7,334,000		(2,554,000	)		10 years
	Mag-Ox® intangible assets			4,100,000		(1,503,000	)		4,100,000		(1,298,000	)		10 years
	Clobetasol intangible asset			4,000,000		(1,400,000	)		4,000,000		(1,200,000	)		10 years
	Orbivan® and Zolvit® intangible assets			3,078,000		(1,258,000	)		3,152,000		(1,028,000	)		3-10 years
	Sinus Buster® intangible assets			2,513,000		(390,000	)		2,513,000		(260,000	)		10 years
	Zolpimist® intangible assets			3,000,000		(1,032,000	)		3,000,000		(844,000	)		10 years
	Zostrix® intangible assets			5,354,000		(3,962,000	)		5,354,000		(3,757,000	)		3-11.5 years
	In-licensed ANDA intangible assets			3,000,000		—			1,500,000		—			10 years
	KVK License intangible assets			1,250,000		(62,000	)		1,250,000		—			10 years
	Midlothian intangible assets			1,011,000		(519,000	)		1,011,000		(460,000	)		3-10 years
	Partnered ANDA intangible assets			500,000		—			500,000		—			10 years
	Vosol® and Vosol® HC intangible assets			700,000		(403,000	)		700,000		(368,000	)		10 years
	Flunisolide intangible assets			1,500,000		(75,000	)		625,000		—			10 years
	Other intangible assets			1,701,000		(1,193,000	)		1,601,000		(1,130,000	)		5-10 years
			$	61,167,000	$	(21,188,000	)	$	58,766,000	$	(17,879,000	)
	(a)	Includes $545,000 of goodwill
	Intangible assets are stated at cost, net of amortization using the straight line method over the expected useful lives of the product rights, once the related products begin to sell. Amortization expense of the intangible assets for the six months ended October 31, 2013 and 2012 was $3,309,000 and $3,518,000, respectively. Amortization expense for the three months ended October 31, 2013 and 2012 was $1,651,000 and $1,761,000, respectively. The Company tests for impairment of intangible assets annually and when events or circumstances indicate that the carrying value of the assets may not be recoverable.
	On June 28, 2011, the Company acquired marketing and distribution rights to several unique branded products for the treatment of pain from Atley Pharmaceuticals. Some products were approved at the time of acquisition and others were subsequently approved by the FDA. The Company paid $3,220,000 in cash for rights to the products and inventory. Inventory acquired was valued at $298,000. The Company also paid an additional $200,000 for Orbivan® CF during the 2012 fiscal year and $100,000 for Orbivan® with Codeine during the 2013 fiscal year. The Company paid an additional $291,000 in connection with this agreement in August 2012, in settlement of any outstanding claims. The Company will pay royalties for certain of these products under a license agreement it has assumed. In July 2011, the Company exercised its option to buy out one of the royalty streams related to one of the products for the amount of $500,000, which was paid in August 2011. Such amount has been included in prepaid royalties. In March 2013, the Company divested Orbivan® for $500,000 over two payments and a royalty stream. The intangible asset is presented at a $3,078,000 value.
	On July 29, 2011, the Company acquired marketing and distribution rights to an ANDA filing from KVK-Tech, Inc. for dexbrompheniramine maleate 6mg/pseudoephedrine sulfate 120mg extended release tablets for $2,000,000. Upon approval from the FDA, the product will be marketed by ECR Pharmaceuticals, the Company’s branded sales and marketing subsidiary, under the Lodrane® brand name. The agreement provided for certain amounts to be refunded to Hi-Tech if the product had not been approved by the FDA by certain dates. As of October 31, 2013, the Company had received refunds of $750,000; therefore, the intangible asset is presented at a $1,250,000 value. The Company began amortizing this asset in May 2013.
	On August 19, 2011, the Company acquired TussiCaps® extended-release capsules and some inventory from Mallinckrodt LLC (“Mallinckrodt”). The Company paid $11,600,000 in cash at the time of acquisition, has made through October 31, 2013 aggregate quarterly payments of $5,750,000 and may make additional payments of up to $6,750,000 over the next three years depending on the competitive landscape and sales performance. On the acquisition date, the Company had recorded a preliminary contingent liability of $11,993,000, which was adjusted to $11,189,000 during the third quarter of fiscal 2012, with the reduction of the contingent liability being offset by a reduction of the related intangible. The fair value of the contingent payment was estimated using the present value of management’s projection of the expected payments pursuant to the term of the agreement. As of October 31, 2013, the contingent payment liability amounted to $6,445,000, of which $2,875,000 is classified as a current liability (see Note [17]). TussiCaps® is covered by two patents which will expire in September 2024 and January 2025. The Company and Mallinckrodt entered into a manufacturing agreement pursuant to which Mallinckrodt will manufacture and supply the TussiCaps® products to the Company through April 2016.
	On November 28, 2011, the Company entered into an asset purchase agreement to acquire an ANDA and related intellectual property for Flunisolide nasal spray. The purchase price of the ANDA and interest in the intellectual property is up to $3,000,000, under certain conditions and is payable in installments over 24 months. In connection with this asset purchase, the Company has entered into a collaboration agreement and profit sharing agreement with another party. The Company and the other party will each own 50% of the product and will each pay equal amounts in satisfaction of the purchase price obligation. The other party will also pay 50% of the development costs and share in 50% of the net profits. The Company made an initial payment of $375,000 on November 29, 2011. On February 28, 2013, the Company made an additional payment of $250,000. During the three months ended July 31, 2013, the Company’s partner launched the product, which triggered the final payment of $875,000. The intangible asset is presented at a $1,500,000 value representing the Company’s 50% share of the product.
	On March 7, 2012, the Company acquired several homeopathic branded nasal spray products including Sinus Buster® and Allergy Buster® from Dynova Laboratories, Inc. for $1,344,000 in cash and an additional $1,250,000 deposited in an escrow account to pay for potential expenses. The balance of the funds in the escrow account in the amount of $767,000 were distributed to Hi-Tech on November 19, 2013. Inventory acquired in the transaction was valued at $82,000. Hi-Tech will also pay a royalty on net sales for 3 1/2 years, or a maximum of $1,750,000, whichever is reached first. The brands are being sold through the Company’s Health Care Products OTC division.
	On December 12, 2012, the Company entered into a license, distribution and supply agreement to acquire the marketing and distribution rights for products containing a controlled substance for a one-time fee of $1,500,000. The Company recorded a $1,500,000 milestone liability during July 2013. In addition, the Company will make payments of $1,000,000 upon the completion of certain additional milestones. Upon approval by the FDA, the product will be marketed by the Company’s generic division. The agreement also requires payments of $1,000,000 per month if the products are the only generic to the brand name drug available for purchase in the territory and certain target unit sales are met. The agreement includes exclusive purchase and supply terms from the manufacturer. Either party may terminate this agreement if any of the terms are not met within noted dates.
	On February 11, 2013, the Company paid $500,000 for marketing and distribution rights for a partnered ANDA pain product.

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Oct. 31, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	9. LONG-TERM DEBT:
	The Company entered into a Revolving Credit Agreement, effective as of June 1, 2010, with JPMorgan Chase (the “Revolving Credit Agreement”). The Revolving Credit Agreement permits the Company to borrow up to $10,000,000 pursuant to a revolving credit note (“Revolving Credit Note”) for, among other things within certain sublimits, general corporate purposes, acquisitions, research and development projects and future stock repurchase programs. Loans shall bear interest at a rate equal to, at the Company’s option, in the case of a CB Floating Rate Loan, as defined in the Revolving Credit Agreement, the Prime Rate, as defined in the Revolving Credit Agreement; provided that, the CB Floating Rate shall never be less than the Adjusted One Month LIBOR Rate, or for a LIBOR Loan, at a rate equal to the Adjusted LIBOR Rate plus the Applicable Margin, as such terms are defined in the Revolving Credit Agreement. The Revolving Credit Agreement contains covenants customary for agreements of this type, including covenants relating to a liquidity ratio, a debt service coverage ratio and a minimum consolidated net income. The Company has not drawn down on this credit facility and had no balance due when the Revolving Credit Agreement expired on May 27, 2013.
	The Company also entered into a $5,000,000 equipment financing agreement with JPMorgan Chase on June 1, 2010. This agreement has similar interest rates. On June 15, 2010 the Company drew down $621,000 of the equipment financing line to fund a down payment for new filling and packaging equipment. On October 13, 2011, the Company borrowed an additional $1,155,000 to finance the remaining payments for the equipment. As of October 31, 2013 the Company has paid all debts related to the equipment financing agreement.

Freight_Expense

Freight Expense	6 Months Ended
	Oct. 31, 2013
Text Block [Abstract]	'
Freight Expense	'
	10. FREIGHT EXPENSE:
	Outgoing freight costs amounted to $2,780,000 and $2,785,000 for the six months ended October 31, 2013 and 2012, respectively, and are included in selling, general, and administrative expense (“SG&A”). Outgoing freight costs amounted to $1,492,000 and $1,477,000 for the three months ended October 31, 2013 and 2012, respectively. Incoming freight is included in cost of goods sold.

Stockholders_Equity

Stockholder's Equity	6 Months Ended
	Oct. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stockholder's Equity	'
	11. STOCK HOLDER’S EQUITY
	[1] Stock-Based Compensation:
	US GAAP requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of US GAAP is recognized as an expense over the requisite service period.
	For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of the applicable accounting guidance.
	The Company’s employee stock options are considered incentive stock options unless they do not meet the requirements for incentive stock options under the Internal Revenue Code. With incentive stock options, there is no tax deferred benefit associated with recording the stock-based compensation.
	The Company recognized stock-based compensation for awards issued under the Company’s Stock Option Plans and Employee Stock Purchase Plan in the following line items in the condensed consolidated statements of operations:
		Three months ended October 31,						Six months ended October 31,
		2013			2012			2013			2012
	Cost of goods sold	$	141,000		$	125,000		$	282,000		$	217,000
	Selling, general and administrative expenses		957,000			735,000			1,914,000			1,271,000
	Research and product development costs		255,000			181,000			499,000			338,000
	Stock-based compensation expense	$	1,353,000		$	1,041,000		$	2,695,000		$	1,826,000
	The Company has elected to use the Black-Scholes option-pricing model, which incorporates various assumptions including volatility, expected life, and interest rate. The expected volatility is based on the historical volatility of the Company’s common stock. The interest rates for periods within the contractual life of the award are based on the United States Treasury yield on the date of each option grant. The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience and vesting schedules of similar awards.
	All options granted through October 31, 2013 had exercise prices equal to the fair market value of the stock on the date of grant, a contractual term of ten years and generally a vesting period of four years. In accordance with US GAAP the Company adjusts share-based compensation on a quarterly basis for changes to the estimate of expected equity award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture rate for all expense amortization after May 1, 2009 is recognized in the period the forfeiture estimate is changed. As of October 31, 2013, the weighted average forfeiture rate was 9% and the effect of forfeiture adjustments for the three and six months ended October 31, 2013 and 2012 was insignificant. On May 22, 2013 the Company granted 40,000 options to an employee for an exercise price of $33.81. On July 16, 2012 the Company granted 442,000 options to directors and employees for an exercise price of $32.59. The Company granted 2,500 employee options on August 1, 2012 for an exercise price of $33.00.
	The following weighted average assumptions were used for the stock options granted during the six months ended October 31, 2013 and 2012:
		May 22, 2013			July 16, 2012			August 1, 2012
	Expected volatility		53	%		54	%		54	%
	Risk-free interest rate		0.91	%		0.6	%		0.6	%
	Expected term		4			4			4
	Expected dividend yield		0	%		0	%		0	%
	Weighted average fair value per share at grant date	$	13.92		$	13.62		$	13.79
	[2] Employee Stock Option Plan:
	In November 2012, the Company adopted the 2012 Incentive Compensation Plan (the “2012 Plan”). The 2012 Incentive Compensation Plan replaces both plans. No new options will be granted under the 2009 Stock Option Plan and the 1994 Directors Stock Option Plan, and the options granted under such plans will continue in effect.
	A summary of the stock option activity and related information for the 2012 Plan for employees for the six months ended October 31, 2013 is as follows:
		Shares			Weighted-Average			Weighted-Average			Aggregate Intrinsic
					Exercise Price			Remaining			Value
								Contractual Term
	Outstanding at May 1, 2013		1,987,000		$	24.03
	Grants		40,000			33.81
	Exercised		(220,000	)		17.74
	Forfeitures or expirations		(22,000	)		28.62
	Outstanding at October 31, 2013		1,785,000		$	24.95			7		$	32,377,000
	Vested and expected to vest at October 31, 2013		1,688,000		$	24.68			6.9		$	31,312,000
	Exercisable at October 31, 2013		705,000		$	17.78			5		$	19,051,000
	[3] Directors Stock Option Plan:
	A summary of the stock option activity and related information for the 2012 Plan for directors for the six months ended October 31, 2013 is as follows:
		Shares			Weighted-Average			Weighted-Average			Aggregate Intrinsic
					Exercise Price			Remaining			Value
								Contractual Term
	Outstanding at May 1, 2013		446,000		$	19.64
	Grants		—			—
	Exercised		(71,000	)		16.98
	Forfeitures or expirations		—			—
	Outstanding at October 31, 2013		375,000		$	20.15			5.5		$	8,608,000
	Vested and expected to vest at October 31, 2013		375,000		$	20.15			5.5		$	8,608,000
	Exercisable at October 31, 2013		250,000		$	15.74			4.1		$	7,083,000
	The aggregate intrinsic values in the preceding tables represent the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $43.09 as of October 31, 2013, which would have been received by the option holders had those option holders exercised their options as of that date.
	The intrinsic value of options exercised for the 2012 Incentive Compensation Plan (the “2012 Plan”) was $7,301,000 and $4,538,000 for the six month periods ended October 31, 2013 and 2012, respectively. As of October 31, 2013, $10,312,000 of total unrecognized compensation cost related to stock options for the 2012 Plan is expected to be recognized over a weighted average period of 2.7 years.
	[4] Treasury Stock:
	On October 7, 2013, in accordance with the 2012 Plan, the Company received 26,000 shares of common stock from David Seltzer, CEO, as payment for the exercise of 75,000 stock options with a value of $1,124,000. The 26,000 shares of common stock received were recorded as treasury stock.
	On January 9, 2013, in accordance with the 2012 Plan, the Company received 35,000 shares of common stock from David Seltzer, CEO, as payment for the exercise of 112,500 stock options with a value of $1,301,000. The 35,000 shares of common stock received were recorded as treasury stock.
	[5] Dividends:
	On November 30, 2012, the Company announced that it would pay a special one-time dividend of $1.50 per share on December 28, 2012 to shareholders of record on December 13, 2012. The Company made a cash payment of $20,176,000 on December 28, 2012 in connection with this dividend.

Product_Divestitures

Product Divestitures	6 Months Ended
	Oct. 31, 2013
Text Block [Abstract]	'
Product Divestitures	'
	12. PRODUCT DIVESTITURES:
	On July 3, 2009 the Company entered into an agreement whereby the Company has granted the marketing rights to certain nutritional products previously marketed by our division, Midlothian Laboratories (“Midlothian”), in exchange for a series of payments totaling $1,000,000 over the course of one year. In addition, the Company received a royalty on the sales of these products, not to exceed $1,500,000 per year for three years ended June 30, 2012. Royalty income earned under this agreement amounted to $0 and $54,000 for the six months ended October 31, 2013 and 2012, respectively. The Company retained this royalty stream when it divested its Midlothian business.
	Effective May 1, 2011, the Company divested Midlothian in exchange for a cash payment of $1,700,000. No gain or loss was recognized on the divesture as the Company had recorded an impairment charge of approximately $1,300,000 at April 30, 2011. The Company retained marketing and distribution rights to generic buprenorphine sublingual tablets, an ANDA that is filed with the FDA, an ANDA that is in development and a royalty stream from products previously divested, as discussed above. Metrics, Inc. acquired Midlothian from the Company.

Income_Taxes

Income Taxes	6 Months Ended
	Oct. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	13. INCOME TAXES:
	The Company estimated its effective tax rate to be approximately 34% for the year ending April 30, 2014. The increase in the effective tax rate compared to the prior period is due to a decrease in the exercises of stock options in the current period. On May 1, 2008, the Company adopted the provisions of ASC Topic 740-10, “Income Taxes” relating to recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company has elected an accounting policy to classify interest and penalties related to unrecognized tax benefits as interest expense. At October 31, 2013 and April 30, 2013, the Company did not have any amount recorded for uncertain tax positions. The Company is no longer subject to U.S. federal, state or local income tax examination for years ended prior to April 30, 2010.

Contingencies_and_Other_Matter

Contingencies and Other Matters	6 Months Ended
	Oct. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies and Other Matters	'
	14. CONTINGENCIES AND OTHER MATTERS:
	[1] Government regulation:
	The Company’s products and facilities are subject to regulation by a number of Federal and State governmental agencies. The Food and Drug Administration (“FDA”), in particular, maintains oversight of the formulation, manufacture, distribution, packaging and labeling of all of the Company’s products. The Drug Enforcement Administration (“DEA”) maintains oversight over the Company’s products that are considered controlled substances.
	On November 20, 2012 through December 13, 2012, the Company was subject to an inspection by the FDA. The inspection resulted in multiple observations on Form 483, an FDA form on which deficiencies are noted after an FDA inspection. The Company responded to those observations on January 3, 2013 and believes that its response to these observations was adequate.
	The Company’s Health Care Products division received a warning letter from the FDA dated July 15, 2013 related to certain statements that appear on labeling of Diabeti-Derm® Antifungal Cream, Zostrix® Diabetic Foot Pain Relief Cream and Zostrix® Diabetic Joint & Arthritis Pain Relief Cream. The Health Care Products division intends to fully comply with the requirements set forth in the warning letter.
	[2] Legal Proceedings:
	A putative class action lawsuit was filed in the Court of Chancery of the State of Delaware on August 30, 2013, captioned Karant v. Hi-Tech Pharmacal Co., Inc., et al., C.A. No. 8854-VCP, in connection with the Agreement and Plan of Merger (the “Merger Agreement”) with Akorn Inc. (“Akorn”) and Akorn Enterprises, Inc., providing for the merger of Akorn Enterprises, Inc. with and into the Company (the “Merger”), alleging, among other things, that Hi-Tech and Hi-Tech’s board of directors breached their fiduciary duties and that Akorn aided and abetted the alleged breaches. The Karant complaint seeks, among other things, injunctive relief enjoining the defendants from completing the Merger and directing the defendants to account to the plaintiff and the purported class for damages allegedly sustained, and an award of fees, expenses and costs.
	In addition, a putative class action lawsuit was filed in Suffolk County, New York, captioned Wackstein v. Hi-Tech Pharmacal Co., Inc., et al., Index No. 063450/2013, similarly alleging, among other things, that Hi-Tech and Hi-Tech’s board of directors breached their fiduciary duties and that Akorn aided and abetted the alleged breaches. The Wackstein complaint seeks, among other things, injunctive relief enjoining the defendants from completing the Merger and directing the defendants to account to the plaintiff and the purported class for damages allegedly sustained, and an award of fees, expenses and costs.
	The defendants believe these lawsuits are without merit but in order to avoid the costs, risks and uncertainties inherent in litigation and to allow stockholders to vote on the proposal to adopt the Merger Agreement and approve the transactions contemplated by the Merger Agreement, including the Merger, at Hi-Tech’s scheduled annual meeting of stockholders, to be held on December 19, 2013, Hi-Tech, Akorn and the other defendants have entered into a memorandum of understanding with plaintiff’s counsel, dated November 26, 2013, in connection with the Karant and Wackstein actions (the “Memorandum of Understanding”), pursuant to which Hi-Tech, Akorn, the other named defendants and Wackstein have agreed to dismiss the Wackstein action with prejudice and pursuant to which Hi-Tech, Akorn, the other named defendants and Karant have agreed to settle the Karant action subject to court approval. If the Delaware court approves the settlement, the Karant action will likewise be dismissed with prejudice.
	On September 11, 2013, the Attorney General of the State of Louisiana filed a lawsuit in Louisiana state court against the Company, and numerous other pharmaceutical companies, under various state laws, alleging that each defendant caused the state’s Medicaid agency to provide reimbursement for drug products that allegedly were not approved by the FDA and therefore allegedly not reimbursable under the federal Medicaid program. Through its lawsuit, the state seeks unspecified damages, statutory fines, penalties, attorney’s fees and costs. On October 15, 2013, the defendants removed the lawsuit to the U.S. District Court for the Middle District of Louisiana. On November 14, 2013, the state filed a motion to remand the lawsuit to the Louisiana state court. While the Company cannot predict the outcome of the lawsuit at this time, it could be subject to material damages, penalties and fines. The Company intends to vigorously defend against all claims in the lawsuit.
	On June 5, 2012, the Company received a notice to preserve documents and electronically stored information in conjunction with a confidential civil investigative demand for information under the Texas Medicaid Fraud Prevention Act, Texas Human Resources Code,§36.001, et seq. relating to the submission of prices to Texas Medicaid in claims for reimbursement for drugs. The Company has engaged independent experts to evaluate the basis of the claim and the underlying data. The Company has submitted information to Texas in response to the request. Texas has indicated that based on its initial review of the data, it is prepared to pursue such claims. While the Company does not know the full extent of its potential liability at this time, it intends to vigorously defend against any such claims should they be pursued. At April 30, 2013, the Company established a contingency loss accrual of $15,500,000 to cover potential settlement or other outcomes. Based on current information and discussions with the State of Texas, the Company increased the contingency loss accrual to $25,000,000 during the second fiscal quarter of 2014. The Company cannot predict that a final settlement or other outcome for such claims will not be higher than the amount accrued nor that such settlement will be reached.
	On August 17, 2011, Allergan, Inc. (“Allergan”) and Duke University filed a complaint against the Company in the United States District Court for the Middle District of North Carolina in response to the Company’s Paragraph IV certifications in its ANDA for Bimatoprost Topical Solution 0.03%, alleging infringement of U.S. Patents Nos. 7,351,404; 7,388,029; and 6,403,649 for Allergan’s product, Latisse. On October 7, 2011, the Company answered the complaint asserting counterclaims. The plaintiffs responded to the counterclaims on October 31, 2011. The claims with respect to U.S. Patent No. 6,403,649 for Allergan’s product were dismissed on February 1, 2012. In November 2012, there was a bench trial on infringement and the validity of U.S. Patent Nos. 7,351,404 and 7,388,029. On January 25, 2013, the Court entered judgment against the Company, finding U.S. Patent Nos. 7,351,404 and 7,388,029 valid and infringed by the Company. The Company filed a Notice of Appeal on February 25, 2013 and filed its opening appellate brief on May 13, 2013 (“Latisse appeal”). The appeal is now fully briefed and the parties are awaiting oral argument. The Company intends to vigorously pursue its appeal of the District Court’s judgment. The Company cannot predict the outcome of the appeal.
	On March 13, 2012, Allergan filed a complaint against the Company in the United States District Court for the Middle District of North Carolina in response to the Company’s Paragraph IV certifications in its ANDA for Bimatoprost Topical Solution 0.03%, alleging infringement of U.S. Patent No. 8,038,988 for Allergan’s product, Latisse. On April 11, 2012 the Company answered the complaint. The case is stayed pending the Latisse appeal. The Company intends to vigorously defend against the allegations in the complaint. The Company cannot predict the outcome of the action.
	On May 16, 2012, Allergan filed a complaint against the Company in the United States District Court for the Middle District of North Carolina in response to the Company’s Paragraph IV certifications in its ANDA for Bimatoprost Topical Solution 0.03%, alleging infringement of U.S. Patent No. 8,101,161 for Allergan’s product, Latisse. The Company answered the complaint on June 14, 2012. The case is stayed pending the Latisse appeal. The Company intends to vigorously defend against the allegations in the complaint. The Company cannot predict the outcome of the action.
	On January 27, 2012, Allergan filed a complaint against the Company in the U.S. District Court for the Eastern District of Texas for infringement of U.S. Patent No. 7,851,504 (“Enhanced Bimatoprost Ophthalmic Solution,” issued December 14, 2010) following a Paragraph IV certification as part of the Company’s filing of an ANDA to manufacture a generic version of Allergan’s Lumigan® 0.01%. On February 23, 2012, the Company answered the complaint. On January 4, 2013, Allergan amended the complaint to assert against the Company claims for infringement of U.S. Patent Nos. 7,851,504; 8,278,353; 8,299,118; 8,309,605; and 8,338,479. The Company answered the amended complaint on February 5, 2013. A bench trial was held on July 15-19, 2013. The Company intends to vigorously defend against the allegations in the amended complaint. The Company cannot predict the outcome of the action.
	On January 8, 2013, Allergan filed a complaint against the Company in the United States District Court for the Middle District of North Carolina in response to the Company’s Paragraph IV certifications in its ANDA for Bimatoprost Topical Solution 0.03%, alleging infringement of U.S. Patent No. 8,263,054 for Allergan’s product, Latisse. On January 30, 2013, the Company answered the complaint. The case is stayed pending the Latisse appeal. The Company intends to vigorously defend against the allegations in the complaint. The Company cannot predict the outcome of the action.
	On October 31, 2011, Senju Pharmaceutical Co.; Kyorin Pharmaceutical Co.; and Allergan filed a complaint in the District Court of Delaware, Civil Action No. 1:11-cv-01059, in response to the Company’s Paragraph IV certification as part of its filing of an ANDA to manufacture a generic version of Allergan’s Zymar® (gatifloxacin ophthalmic solution, 0.3%). The complaint alleges infringement of U.S. Patent Nos. 6,333,045 (“Aqueous Liquid Pharmaceutical Composition Comprised of Gatifloxacin,” issued on December 25, 2001) and 5,880,283 (“8-Alkoxyquinolonecarboxylic Acid Hydrate With Excellent Stability And Process For Producing The Same,” issued March 9, 1999), licensed to Allergan. On December 16, 2011, the Company answered the complaint. On August 28, 2012, the claims on U.S. Patent No. 5,880,283 were dismissed. In January 2013, a bench trial on the validity and infringement of U.S. Patent No. 6,333,045 took place in this matter. On August 9, 2013, the Court issued its opinion finding the ‘045 patent invalid. The plaintiffs have appealed the district court’s decision to the U.S. Court of Appeals for the Federal Circuit.
	On October 11, 2011, Senju Pharmaceutical Co.; Kyorin Pharmaceutical Co.; and Allergan filed a complaint in the District Court of Delaware, Civil Action No. 1:11-cv-00926; in response to the Company’s Paragraph IV certification as part of its filing of an ANDA to manufacture a generic version of Allergan’s Zymaxid® (gatifloxacin ophthalmic solution, 0.5%). The complaint alleges infringement of U.S. Patent Nos. 6,333,045 (“Aqueous Liquid Pharmaceutical Composition Comprised of Gatifloxacin,” issued December 25, 2001) and 5,880,283 (“8-Alkoxyquinolonecarboxylic Acid Hydrate With Excellent Stability and Process for Producing the Same,” issued March 9, 1999), licensed to Allergan. On December 16, 2011, the Company answered the complaint. On August 28, 2012, the claims on U.S. Patent No. 5,880,283 were dismissed. In January 2013, a bench trial on the validity and infringement of U.S. Patent No. 6,333,045 took place in this matter. On August 9, 2013, the Court issued its opinion finding the ‘045 patent invalid. The plaintiffs have appealed the district court’s decision to the U.S. Court of Appeals for the Federal Circuit.
	On June 8, 2012, plaintiff Mathew Harrison, on behalf of himself and all others similarly situated, brought a class action lawsuit, Civil Action No. 12-2897, in the U.S. District Court for the Eastern District of New York, against Wayne Perry, Dynova Laboratories, Inc., Sicap Industries, LLC, Walgreens Co. and the Company (“Harrison case”). On May 16, 2012, plaintiff David Delre, on behalf of himself and all others similarly situated, brought a class action lawsuit, Civil Action No. 12-2429, in the U.S. District Court for the Eastern District of New York, against Wayne Perry, Dynova Laboratories, Inc., Sicap Industries, LLC, and the Company. Each complaint alleges, among other things, that their Sinus Buster® products are improperly marketed, labeled and sold as homeopathic products, and that these allegations support claims of fraud, unjust enrichment, breach of express and implied warranties and alleged violations of various state and federal statutes. The Company answered the complaints on July 17, 2012 and June 26, 2012, respectively, and asserted cross-claims against the other defendants, except Walgreens which was dismissed from the Harrison case. The Court consolidated these two cases into one action entitled Sinus Buster Products Consumer Litigation. Discovery commenced in the consolidated case, but is stayed while the parties negotiate a possible settlement. Dynova has filed for bankruptcy. The case is now proceeding without Dynova. A discovery schedule for depositions, expert discovery and class certification motion is in place. These dates are on hold until the next Court conference to allow for the negotiation of a possible settlement. The Company intends to vigorously defend against the allegations in the complaint and the class certification, if the case does not settle. The Company has established a contingency loss accrual of $700,000 included in accrued legal settlements to cover potential settlement, or other outcomes, but cannot predict that settlement on terms deemed acceptable to the Company will occur.
	On February 9, 2010, in the United States District Court for the District of Massachusetts (the “Federal District Court”), a “Partial Unsealing Order” was issued and unsealed in a civil case naming several pharmaceutical companies as defendants under the qui tam provisions of the federal civil False Claims Act (the “Qui Tam Complaint”). The qui tam provisions permit a private person, known as a “relator” (sometimes referred to as a “whistleblower”), to file civil actions under this statute on behalf of the federal and state governments. Pursuant to the Order, a Revised Corrected Seventh Amended Complaint was filed by the relator and unsealed on February 10, 2010. The relator in the Complaint is Constance A. Conrad. The Complaint alleges that several pharmaceutical companies submitted false records or statements to the United States through the Center for Medicare and Medicaid Services (“CMS”) and thereby caused false claims for payments to be made through state Medicaid Reimbursement programs for unapproved or ineffective drugs or for products that are not drugs at all. The Complaint alleges that the drugs were “New Drugs” that the FDA had not approved and that are expressly excluded from the definition of “Covered Outpatient Drugs”, which would have rendered them eligible for Medicaid reimbursement. The Complaint alleges these actions violate the federal civil False Claims Act. The Revised Corrected Seventh Amended Complaint did not name the Company as a defendant.
	On February 9, 2010, the Court also unsealed the “United States’ Notice of Partial Declination” in which the government determined not to intervene against 68 named defendants, including the Company. On July 23, 2010, the relator further amended the Complaint, which, as amended, named the Company, including a subsidiary of the Company, as a defendant. On January 6, 2011, the Court issued an order unsealing the government’s notice of election to intervene as to a previously unnamed defendant. On July 25, 2011, the Court issued an order stating, among other things, that all parties agreed that the only defendant against whom the United States has elected to intervene is the previously unnamed defendant. On July 26, 2011, the relator filed its Tenth Amended Complaint, which removed the allegations against the Company’s subsidiary, but not the Company, realleging them against another party. The Company previously indicated that it intended to vigorously defend against the remaining allegations in the relator’s Complaint, and that it could not predict the outcome of the action. On February 25, 2013, the Court issued a decision granting the motion that had been filed by the Company and other defendants to dismiss the Complaint, which could be subject to appeal.
	On December 12, 2012, plaintiff Linda Hoover, on behalf of herself and all others similarly situated, brought a class action lawsuit against the Company in the Superior Court for the State of California, which the Company removed to the U.S. District Court for the Central District of California, Civil Action No. 5:2013-0097, alleging that the Company’s marketing and sales of its Nasal Ease® product is a violation of various state statutes, including the Consumer Legal Remedies Act, California’s False Advertising Law and Unlawful, Fraudulent & Unfair Business Practices Act. The Company answered the complaint on January 14, 2013. The parties have reached a settlement in this action as set forth in the Class Action Settlement Agreement, dated as of August 15, 2013. The motion for preliminary approval was submitted to the Court on August 23, 2013, and the Court issued its preliminary approval on September 27, 2013. The Company has established a contingency loss accrual of $700,000 included in accrued legal settlements in connection with this complaint.
	[3] Commitments and Contingencies:
	The Company’s ECR Pharmaceuticals subsidiary currently leases approximately 12,000 square feet in Richmond, VA. This lease ends August 31, 2014.
	In June 2010, the Company entered into an agreement to lease a parking lot in Amityville, NY. The Company will pay $90,000 over a five year period.
	In the course of its business, the Company enters into agreements which require the Company to make royalty payments which are generally based on net sales or gross profits of certain products.
	In connection with the TussiCaps® acquisition, the Company entered into a manufacturing agreement which requires the Company to make a minimum purchase of $500,000 in the first year and $1,000,000 per year over the next four years.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
	Oct. 31, 2013
Accounting Changes And Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	15. RECENT ACCOUNTING PRONOUNCEMENTS:
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued guidance regarding the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. Under this new guidance, companies must present this unrecognized tax benefit in the financial statements as a reduction to deferred tax assets created by net operating losses or other tax credits from prior periods that occur in the same taxing jurisdiction. If the unrecognized tax benefit exceeds such credits it should be presented in the financial statements as a liability. This update is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2013. The adoption of this standard is not expected to have a material impact on the Company’s results of operations, cash flows or financial position.
	In February 2013, the FASB issued guidance related to additional reporting and disclosure of amounts reclassified out of accumulated other comprehensive income (“OCI”). Under this new guidance, companies will be required to disclose the amount of income or loss reclassified out of OCI to each respective line item on the income statement where net income is presented. The guidance allows companies to elect whether to disclose the reclassification either in the notes to the financial statements, or on the face of the income statement. This update was effective for annual and interim reporting periods for fiscal years beginning after December 15, 2012. The adoption of this standard had no material impact on the Company’s results of operations, cash flows or financial position.
	In July 2012, the FASB issued accounting guidance to simplify the evaluation for impairment of indefinite-lived intangible assets. Under the updated guidance, an entity has the option of first performing a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired before proceeding to the quantitative impairment test under which it would calculate the asset’s fair value. When performing the qualitative assessment, the entity must evaluate events and circumstances that may affect the significant inputs used to determine the fair value of the indefinite-lived intangible asset. This guidance was effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The adoption of this standard had no material impact on the Company’s results of operations, cash flows or financial position.

Significant_Customers_and_Conc

Significant Customers and Concentration of Credit Risk	6 Months Ended
	Oct. 31, 2013
Risks And Uncertainties [Abstract]	'
Significant Customers and Concentration of Credit Risk	'
	16. SIGNIFICANT CUSTOMERS AND CONCENTRATION OF CREDIT RISK:
	The table below presents the percentages of our net sales and gross trade accounts receivable attributed to each of our top four customers as of and for the six months ended October 31, 2013 and 2012:
		October 31,
		2013						2012
		Net Sales			Gross Accounts			Net Sales			Gross Accounts
					Receivable						Receivable
	AmerisourceBergen Corporation		17	%		17	%		14	%		15	%
	Cardinal Health, Inc.		12	%		14	%		13	%		13	%
	McKesson Corporation		16	%		24	%		21	%		25	%
	Walgreens		19	%		12	%		17	%		14	%
	Combined total		64	%		67	%		65	%		67	%
	The Company maintains cash and cash equivalents primarily with major financial institutions. Such amounts exceed Federal Deposit Insurance Company limits.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Oct. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	17. FAIR VALUE MEASUREMENTS:
	The accounting guidance under ASC “Fair Value Measurements and Disclosures” (“ASC 820-10”) utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. A brief description of those levels is as follows:
		•		Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.
		•		Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
		•		Level 3: Significant unobservable inputs.
	The Company’s financial liabilities subject to fair value measurements as of October 31, 2013 were as follows:
	Fair Value Measurements Using Fair Value Hierarchy
			Fair Value			Level 3
	Contingent payment liability		$	6,445,000		$	6,445,000
	The Company’s financial liabilities subject to fair value measurements as of April 30, 2013 were as follows:
	Fair Value Measurements Using Fair Value Hierarchy
			Fair Value			Level 3
	Contingent payment liability		$	7,719,000		$	7,719,000
	The following table presents the roll forward of the Company’s contingent payment liability as of October 31, 2013.
	Contingent payment liability—May 1, 2013		$	7,719,000
	Payments on contingent liability			(1,438,000	)
	Interest expense			164,000
	Contingent payment liability—October 31, 2013		$	6,445,000
	The fair value of the contingent payment liability was estimated using the present value of management’s projection of the expected payments pursuant to the term of the TussiCaps® agreement (see Note 8). The present value of the contingent liability was computed using a discount rate of 5.2%.
	The carrying value of certain financial instruments such as cash and cash equivalents, accounts receivable and accounts payable approximates their fair values due to their short-term nature of their underlying terms. The carrying value of the long-term debt approximates its fair value based upon its variable market interest rates, which approximates current market interest.

Segment_Information

Segment Information	6 Months Ended
	Oct. 31, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	18. SEGMENT INFORMATION:
	The Company operates in three reportable business segments: generic pharmaceuticals (referred to as “Hi-Tech Generic”), OTC branded pharmaceuticals (referred to as “Health Care Products”, or “HCP”) and prescription brands (referred to as “ECR”). Branded products are marketed under brand names through marketing programs that are designed to generate physician and consumer loyalty. Generic pharmaceutical products are the chemical and therapeutic equivalents of corresponding brand drugs. Our Chief Operating Decision Maker is our Chief Executive Officer.
	The business segments were determined based on management’s reporting and decision-making requirements in accordance with FASB ASC 280-10 Segment Reporting. The generic products represent a single operating segment because the demand for these products is mainly driven by consumers seeking a lower cost alternative to brand name drugs. Certain of our expenses, such as the direct sales force and other sales and marketing expenses and specific research and development expenses, are charged directly to the respective segments. Other expenses, such as general and administrative expenses, are included under the Corporate and other cost heading.
		Hi-Tech			HCP			ECR			Corp/Other			Total
	For the three months ended October 31, 2013
	Net sales	$	47,732,000		$	4,100,000		$	6,769,000		$	—		$	58,601,000
	Cost of goods sold		24,241,000			1,576,000			1,474,000			—			27,291,000
	Gross profit	$	23,491,000		$	2,524,000		$	5,295,000		$	—		$	31,310,000
	Amortization expense		(209,000	)		(270,000	)		(1,172,000	)		—			(1,651,000	)
	Income (loss) before income taxes	$	16,241,000		$	976,000		$	257,000		$	(15,699,000	)	$	1,775,000
	For the three months ended October 31, 2012
	Net sales	$	47,286,000		$	4,658,000		$	5,593,000		$	—		$	57,537,000
	Cost of goods sold		24,434,000			1,984,000			1,530,000			—			27,948,000
	Gross profit	$	22,852,000		$	2,674,000		$	4,063,000		$	—		$	29,589,000
	Amortization expense		(278,000	)		(304,000	)		(1,179,000	)		—			(1,761,000	)
	Income (loss) before income taxes	$	17,371,000		$	(3,000	)	$	(134,000	)	$	(4,123,000	)	$	13,111,000
		Hi-Tech			HCP			ECR			Corp/Other			Total
	For the six months ended October 31, 2013
	Net sales	$	91,261,000		$	7,583,000		$	10,258,000		$	—		$	109,102,000
	Cost of goods sold		47,084,000			3,004,000			2,279,000			—			52,367,000
	Gross profit	$	44,177,000		$	4,579,000		$	7,979,000		$	—		$	56,735,000
	Amortization expense		(419,000	)		(540,000	)		(2,350,000	)		—			(3,309,000	)
	Income (loss) before income taxes	$	30,810,000		$	805,000		$	(2,382,000	)	$	(20,568,000	)	$	8,665,000
	For the six months ended October 31, 2012
	Net sales	$	93,208,000		$	7,684,000		$	8,688,000		$	—		$	109,580,000
	Cost of goods sold		49,158,000			3,324,000			2,188,000			—			54,670,000
	Gross profit	$	44,050,000		$	4,360,000		$	6,500,000		$	—		$	54,910,000
	Amortization expense		(591,000	)		(574,000	)		(2,353,000	)		—			(3,518,000	)
	Income (loss) before income taxes	$	32,185,000		$	(746,000	)	$	(1,931,000	)	$	(7,411,000	)	$	22,097,000

Subsequent_Events

Subsequent Events	6 Months Ended
	Oct. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	19. SUBSEQUENT EVENTS:
	The Company filed a Proxy Statement Supplement with the Securities and Exchange Commission on November 27, 2013, supplementing the disclosure contained in the Company’s Definitive Proxy Statement filed on November 7, 2013 in connection with the Merger.
	The Company entered into a memorandum of understanding, dated November 26, 2013, with the plaintiff’s counsel in connection with the Karant and Wackstein actions, more fully described in Note [14], Legal Proceedings.

Income_Taxes_Policies

Income Taxes (Policies)	6 Months Ended
	Oct. 31, 2013
Accounting Changes And Error Corrections [Abstract]	'
Income Taxes	'
	The Company estimated its effective tax rate to be approximately 34% for the year ending April 30, 2014. The increase in the effective tax rate compared to the prior period is due to a decrease in the exercises of stock options in the current period. On May 1, 2008, the Company adopted the provisions of ASC Topic 740-10, “Income Taxes” relating to recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company has elected an accounting policy to classify interest and penalties related to unrecognized tax benefits as interest expense. At October 31, 2013 and April 30, 2013, the Company did not have any amount recorded for uncertain tax positions. The Company is no longer subject to U.S. federal, state or local income tax examination for years ended prior to April 30, 2010.
Comprehensive Income	'
	In February 2013, the FASB issued guidance related to additional reporting and disclosure of amounts reclassified out of accumulated other comprehensive income (“OCI”). Under this new guidance, companies will be required to disclose the amount of income or loss reclassified out of OCI to each respective line item on the income statement where net income is presented. The guidance allows companies to elect whether to disclose the reclassification either in the notes to the financial statements, or on the face of the income statement. This update was effective for annual and interim reporting periods for fiscal years beginning after December 15, 2012. The adoption of this standard had no material impact on the Company’s results of operations, cash flows or financial position.
Indefinite-lived Intangible Assets	'
	In July 2012, the FASB issued accounting guidance to simplify the evaluation for impairment of indefinite-lived intangible assets. Under the updated guidance, an entity has the option of first performing a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired before proceeding to the quantitative impairment test under which it would calculate the asset’s fair value. When performing the qualitative assessment, the entity must evaluate events and circumstances that may affect the significant inputs used to determine the fair value of the indefinite-lived intangible asset. This guidance was effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The adoption of this standard had no material impact on the Company’s results of operations, cash flows or financial position.
Fair Value of Financial Instruments	'
	The accounting guidance under ASC “Fair Value Measurements and Disclosures” (“ASC 820-10”) utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. A brief description of those levels is as follows:
		•	Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.
		•	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
		•	Level 3: Significant unobservable inputs.
Segment Reporting	'
	The business segments were determined based on management’s reporting and decision-making requirements in accordance with FASB ASC 280-10 Segment Reporting. The generic products represent a single operating segment because the demand for these products is mainly driven by consumers seeking a lower cost alternative to brand name drugs. Certain of our expenses, such as the direct sales force and other sales and marketing expenses and specific research and development expenses, are charged directly to the respective segments. Other expenses, such as general and administrative expenses, are included under the Corporate and other cost heading.

Accounts_Receivable_Tables

Accounts Receivable (Tables)	6 Months Ended
	Oct. 31, 2013
Receivables [Abstract]	'
Accounts Receivable Balances, Net of Returns and Allowances and Allowance for Doubtful Accounts	'
	At October 31, 2013 and April 30, 2013, accounts receivable balances, net of returns and allowances and allowance for doubtful accounts, are as follows:
			October 31, 2013			April 30, 2013
	Accounts receivable, gross		$	93,310,000		$	86,457,000
	Adjustment for returns and price allowances (a)			(23,794,000	)		(22,182,000	)
	Allowance for doubtful accounts			(500,000	)		(500,000	)
	Accounts receivable, net		$	69,016,000		$	63,775,000
	(a)	directly reduces gross revenue
Roll Forward of Each Significant Accounts Receivable Estimate	'
	The following table presents the roll forward of each significant estimate as of October 31, 2013 and October 31, 2012 and for the six months then ended, respectively.
	For the six months ended October 31, 2013		Beginning			Current			Actual Credits			Ending
			Balance			Provision			in Current			Balance
			May 1						Period			October 31
	Chargebacks		$	13,357,000		$	88,374,000		$	(88,313,000	)	$	13,418,000
	Sales discounts			1,950,000			4,910,000			(4,809,000	)		2,051,000
	Sales allowances & returns			6,875,000			24,836,000			(23,386,000	)		8,325,000
	Total adjustment for returns & price allowances		$	22,182,000		$	118,120,000		$	(116,508,000	)	$	23,794,000
	For the six months ended October 31, 2012
	Chargebacks		$	10,477,000		$	70,222,000		$	(70,458,000	)	$	10,241,000
	Sales discounts			1,813,000			4,555,000			(4,214,000	)		2,154,000
	Sales allowances & returns			5,745,000			25,516,000			(22,307,000	)		8,954,000
	Total adjustment for returns & price allowances		$	18,035,000		$	100,293,000		$	(96,979,000	)	$	21,349,000

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Oct. 31, 2013
Inventory Disclosure [Abstract]	'
Components of Inventory	'
	The components of inventory consist of the following:
		October 31,		April 30,
		2013		2013
	Finished goods	$	18,285,000	$	14,575,000
	Work in process		311,000		352,000
	Raw materials		27,283,000		24,302,000
	Total inventory	$	45,879,000	$	39,229,000

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Oct. 31, 2013
Property Plant And Equipment [Abstract]	'
Components of Property and Equipment	'
	The components of property and equipment consist of the following:
		October 31,		April 30,
		2013		2013
	Land and building and improvements	$	21,989,000	$	21,592,000
	Machinery and equipment		39,150,000		35,145,000
	Transportation equipment		69,000		69,000
	Computer equipment and systems		7,567,000		6,866,000
	Furniture and fixtures		1,352,000		1,313,000
		$	70,127,000	$	64,985,000
	Accumulated depreciation and amortization		35,116,000		32,817,000
	Total property and equipment	$	35,011,000	$	32,168,000

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Oct. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Components of Net Intangible Assets	'
	The components of net intangible assets are as follows:
			October 31, 2013					April 30, 2013
			Gross Carrying		Accumulated			Gross Carrying		Accumulated			Amortization Period
			Amount		Amortization			Amount		Amortization
	TussiCaps® intangible assets		$	22,126,000	$	(6,474,000	)	$	22,126,000	$	(4,980,000	)		5-10 years
	ECR intangible assets (a)			7,334,000		(2,917,000	)		7,334,000		(2,554,000	)		10 years
	Mag-Ox® intangible assets			4,100,000		(1,503,000	)		4,100,000		(1,298,000	)		10 years
	Clobetasol intangible asset			4,000,000		(1,400,000	)		4,000,000		(1,200,000	)		10 years
	Orbivan® and Zolvit® intangible assets			3,078,000		(1,258,000	)		3,152,000		(1,028,000	)		3-10 years
	Sinus Buster® intangible assets			2,513,000		(390,000	)		2,513,000		(260,000	)		10 years
	Zolpimist® intangible assets			3,000,000		(1,032,000	)		3,000,000		(844,000	)		10 years
	Zostrix® intangible assets			5,354,000		(3,962,000	)		5,354,000		(3,757,000	)		3-11.5 years
	In-licensed ANDA intangible assets			3,000,000		—			1,500,000		—			10 years
	KVK License intangible assets			1,250,000		(62,000	)		1,250,000		—			10 years
	Midlothian intangible assets			1,011,000		(519,000	)		1,011,000		(460,000	)		3-10 years
	Partnered ANDA intangible assets			500,000		—			500,000		—			10 years
	Vosol® and Vosol® HC intangible assets			700,000		(403,000	)		700,000		(368,000	)		10 years
	Flunisolide intangible assets			1,500,000		(75,000	)		625,000		—			10 years
	Other intangible assets			1,701,000		(1,193,000	)		1,601,000		(1,130,000	)		5-10 years
			$	61,167,000	$	(21,188,000	)	$	58,766,000	$	(17,879,000	)
	(a)	Includes $545,000 of goodwill

Stockholders_Equity_Tables

Stockholder's Equity (Tables)	6 Months Ended
	Oct. 31, 2013
Stock-based Compensation Expense before Income Tax Benefit	'
	The Company recognized stock-based compensation for awards issued under the Company’s Stock Option Plans and Employee Stock Purchase Plan in the following line items in the condensed consolidated statements of operations:
		Three months ended October 31,						Six months ended October 31,
		2013			2012			2013			2012
	Cost of goods sold	$	141,000		$	125,000		$	282,000		$	217,000
	Selling, general and administrative expenses		957,000			735,000			1,914,000			1,271,000
	Research and product development costs		255,000			181,000			499,000			338,000
	Stock-based compensation expense	$	1,353,000		$	1,041,000		$	2,695,000		$	1,826,000
Weighted Average Assumptions Used for Stock Options Granted	'
	The following weighted average assumptions were used for the stock options granted during the six months ended October 31, 2013 and 2012:
		May 22, 2013			July 16, 2012			August 1, 2012
	Expected volatility		53	%		54	%		54	%
	Risk-free interest rate		0.91	%		0.6	%		0.6	%
	Expected term		4			4			4
	Expected dividend yield		0	%		0	%		0	%
	Weighted average fair value per share at grant date	$	13.92		$	13.62		$	13.79
Employee Stock Option Plan [Member]	'
Summary of Stock Option Activity and Related Information for Stock Option Plan	'
	A summary of the stock option activity and related information for the 2012 Plan for employees for the six months ended October 31, 2013 is as follows:
		Shares			Weighted-Average			Weighted-Average			Aggregate Intrinsic
					Exercise Price			Remaining			Value
								Contractual Term
	Outstanding at May 1, 2013		1,987,000		$	24.03
	Grants		40,000			33.81
	Exercised		(220,000	)		17.74
	Forfeitures or expirations		(22,000	)		28.62
	Outstanding at October 31, 2013		1,785,000		$	24.95			7		$	32,377,000
	Vested and expected to vest at October 31, 2013		1,688,000		$	24.68			6.9		$	31,312,000
	Exercisable at October 31, 2013		705,000		$	17.78			5		$	19,051,000
Directors Stock Option Plan [Member]	'
Summary of Stock Option Activity and Related Information for Stock Option Plan	'
	A summary of the stock option activity and related information for the 2012 Plan for directors for the six months ended October 31, 2013 is as follows:
		Shares			Weighted-Average			Weighted-Average			Aggregate Intrinsic
					Exercise Price			Remaining			Value
								Contractual Term
	Outstanding at May 1, 2013		446,000		$	19.64
	Grants		—			—
	Exercised		(71,000	)		16.98
	Forfeitures or expirations		—			—
	Outstanding at October 31, 2013		375,000		$	20.15			5.5		$	8,608,000
	Vested and expected to vest at October 31, 2013		375,000		$	20.15			5.5		$	8,608,000
	Exercisable at October 31, 2013		250,000		$	15.74			4.1		$	7,083,000

Significant_Customers_and_Conc1

Significant Customers and Concentration of Credit Risk (Tables)	6 Months Ended
	Oct. 31, 2013
Risks And Uncertainties [Abstract]	'
Percentages of Net Sales and Gross Trade Accounts Receivable Attributed to Each Customer	'
	The table below presents the percentages of our net sales and gross trade accounts receivable attributed to each of our top four customers as of and for the six months ended October 31, 2013 and 2012:
		October 31,
		2013						2012
		Net Sales			Gross Accounts			Net Sales			Gross Accounts
					Receivable						Receivable
	AmerisourceBergen Corporation		17	%		17	%		14	%		15	%
	Cardinal Health, Inc.		12	%		14	%		13	%		13	%
	McKesson Corporation		16	%		24	%		21	%		25	%
	Walgreens		19	%		12	%		17	%		14	%
	Combined total		64	%		67	%		65	%		67	%

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Oct. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Financial Liabilities Subject to Fair Value Measurements	'
	The Company’s financial liabilities subject to fair value measurements as of October 31, 2013 were as follows:
	Fair Value Measurements Using Fair Value Hierarchy
		Fair Value			Level 3
	Contingent payment liability	$	6,445,000		$	6,445,000
	The Company’s financial liabilities subject to fair value measurements as of April 30, 2013 were as follows:
	Fair Value Measurements Using Fair Value Hierarchy
		Fair Value			Level 3
	Contingent payment liability	$	7,719,000		$	7,719,000
Roll Forward of Contingent Payment Liability	'
	The following table presents the roll forward of the Company’s contingent payment liability as of October 31, 2013.
	Contingent payment liability—May 1, 2013	$	7,719,000
	Payments on contingent liability		(1,438,000	)
	Interest expense		164,000
	Contingent payment liability—October 31, 2013	$	6,445,000

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Oct. 31, 2013
Segment Reporting [Abstract]	'
Operating Income from Reportable Business Segments before Income Taxes	'
		Hi-Tech			HCP			ECR			Corp/Other			Total
	For the three months ended October 31, 2013
	Net sales	$	47,732,000		$	4,100,000		$	6,769,000		$	—		$	58,601,000
	Cost of goods sold		24,241,000			1,576,000			1,474,000			—			27,291,000
	Gross profit	$	23,491,000		$	2,524,000		$	5,295,000		$	—		$	31,310,000
	Amortization expense		(209,000	)		(270,000	)		(1,172,000	)		—			(1,651,000	)
	Income (loss) before income taxes	$	16,241,000		$	976,000		$	257,000		$	(15,699,000	)	$	1,775,000
	For the three months ended October 31, 2012
	Net sales	$	47,286,000		$	4,658,000		$	5,593,000		$	—		$	57,537,000
	Cost of goods sold		24,434,000			1,984,000			1,530,000			—			27,948,000
	Gross profit	$	22,852,000		$	2,674,000		$	4,063,000		$	—		$	29,589,000
	Amortization expense		(278,000	)		(304,000	)		(1,179,000	)		—			(1,761,000	)
	Income (loss) before income taxes	$	17,371,000		$	(3,000	)	$	(134,000	)	$	(4,123,000	)	$	13,111,000
		Hi-Tech			HCP			ECR			Corp/Other			Total
	For the six months ended October 31, 2013
	Net sales	$	91,261,000		$	7,583,000		$	10,258,000		$	—		$	109,102,000
	Cost of goods sold		47,084,000			3,004,000			2,279,000			—			52,367,000
	Gross profit	$	44,177,000		$	4,579,000		$	7,979,000		$	—		$	56,735,000
	Amortization expense		(419,000	)		(540,000	)		(2,350,000	)		—			(3,309,000	)
	Income (loss) before income taxes	$	30,810,000		$	805,000		$	(2,382,000	)	$	(20,568,000	)	$	8,665,000
	For the six months ended October 31, 2012
	Net sales	$	93,208,000		$	7,684,000		$	8,688,000		$	—		$	109,580,000
	Cost of goods sold		49,158,000			3,324,000			2,188,000			—			54,670,000
	Gross profit	$	44,050,000		$	4,360,000		$	6,500,000		$	—		$	54,910,000
	Amortization expense		(591,000	)		(574,000	)		(2,353,000	)		—			(3,518,000	)
	Income (loss) before income taxes	$	32,185,000		$	(746,000	)	$	(1,931,000	)	$	(7,411,000	)	$	22,097,000

Business_Additional_Informatio

Business - Additional Information (Detail) (USD $)	0 Months Ended
	Aug. 26, 2013	Oct. 31, 2013	Apr. 30, 2013
Business Combinations [Abstract]	'	'	'
Common stock, par value	$0.01	$0.01	$0.01
Cash consideration per share on surrender of outstanding shares	$43.50	'	'
Termination fee receivable by parent on or before agreement expiration date	$41,639,000	'	'
Termination fee receivable by parent after agreement expiration date	48,045,000	'	'
Termination fee payable to parent as per agreement	20,819,000	'	'
Termination fee payable to parent under exceptional circumstances	$32,030,000	'	'

Net_Income_Per_Share_Additiona

Net Income Per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Earnings Per Share [Abstract]	'	'	'	'
Number of potentially dilutive securities excluded from the computation of diluted income per share	0	40,000	0	40,000

Accounts_Receivable_Accounts_R

Accounts Receivable - Accounts Receivable Balances, Net of Returns and Allowances and Allowance for Doubtful Accounts (Detail) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Receivables [Abstract]	'	'
Accounts receivable, gross	$93,310,000	$86,457,000
Adjustment for returns and price allowances	-23,794,000	-22,182,000
Allowance for doubtful accounts	-500,000	-500,000
Accounts receivable, net	$69,016,000	$63,775,000

Accounts_Receivable_Additional

Accounts Receivable - Additional Information (Detail)	6 Months Ended
	Oct. 31, 2013
Receivables [Abstract]	'
Chargeback activity represented by wholesalers	95.00%
Accounts receivable discount assumption rate	100.00%

Accounts_Receivable_Roll_Forwa

Accounts Receivable - Roll Forward of Each Significant Accounts Receivable Estimate (Detail) (USD $)	6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Balance at Beginning of Period	$22,182,000	$18,035,000
Current Provision	118,120,000	100,293,000
Actual Credits in Current Period	-116,508,000	-96,979,000
Balance at End of Period	23,794,000	21,349,000
Chargebacks [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Balance at Beginning of Period	13,357,000	10,477,000
Current Provision	88,374,000	70,222,000
Actual Credits in Current Period	-88,313,000	-70,458,000
Balance at End of Period	13,418,000	10,241,000
Sales discounts [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Balance at Beginning of Period	1,950,000	1,813,000
Current Provision	4,910,000	4,555,000
Actual Credits in Current Period	-4,809,000	-4,214,000
Balance at End of Period	2,051,000	2,154,000
Sales allowances & returns [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Balance at Beginning of Period	6,875,000	5,745,000
Current Provision	24,836,000	25,516,000
Actual Credits in Current Period	-23,386,000	-22,307,000
Balance at End of Period	$8,325,000	$8,954,000

Inventory_Components_of_Invent

Inventory - Components of Inventory (Detail) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Inventory Disclosure [Abstract]	'	'
Finished goods	$18,285,000	$14,575,000
Work in process	311,000	352,000
Raw materials	27,283,000	24,302,000
Total inventory	$45,879,000	$39,229,000

Property_and_Equipment_Compone

Property and Equipment - Components of Property and Equipment (Detail) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$70,127,000	$64,985,000
Accumulated depreciation and amortization	35,116,000	32,817,000
Total property and equipment	35,011,000	32,168,000
Land and building and improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	21,989,000	21,592,000
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	39,150,000	35,145,000
Transportation equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	69,000	69,000
Computer equipment and systems [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	7,567,000	6,866,000
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$1,352,000	$1,313,000

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012	Apr. 30, 2013
Property Plant And Equipment [Abstract]	'	'	'	'	'
Depreciation expense	$1,163,000	$1,007,000	$2,299,000	$1,936,000	'
Land, carrying value	$1,860,000	'	$1,860,000	'	$1,860,000

Intangible_Assets_Components_o

Intangible Assets - Components of Net Intangible Assets (Detail) (USD $)

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Mar. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2013

Oct. 31, 2013

TussiCaps intangible assets [Member]

TussiCaps intangible assets [Member]

TussiCaps intangible assets [Member]

TussiCaps intangible assets [Member]

ECR intangible assets [Member]

ECR intangible assets [Member]

ECR intangible assets [Member]

ECR intangible assets [Member]

Mag-Ox intangible assets [Member]

Mag-Ox intangible assets [Member]

Mag-Ox intangible assets [Member]

Mag-Ox intangible assets [Member]

Clobetasol intangible asset [Member]

Clobetasol intangible asset [Member]

Clobetasol intangible asset [Member]

Clobetasol intangible asset [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Sinus Buster intangible assets [Member]

Sinus Buster intangible assets [Member]

Sinus Buster intangible assets [Member]

Sinus Buster intangible assets [Member]

Zolpimist intangible assets [Member]

Zolpimist intangible assets [Member]

Zolpimist intangible assets [Member]

Zolpimist intangible assets [Member]

Zostrix intangible assets [Member]

Zostrix intangible assets [Member]

Zostrix intangible assets [Member]

Zostrix intangible assets [Member]

In-licensed ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

Midlothian intangible assets [Member]

Midlothian intangible assets [Member]

Midlothian intangible assets [Member]

Midlothian intangible assets [Member]

Partnered ANDA intangible assets [Member]

Partnered ANDA intangible assets [Member]

Partnered ANDA intangible assets [Member]

Partnered ANDA intangible assets [Member]

Vosol and Vosol HC intangible assets [Member]

Vosol and Vosol HC intangible assets [Member]

Vosol and Vosol HC intangible assets [Member]

Vosol and Vosol HC intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Other intangible assets [Member]

Other intangible assets [Member]

Other intangible assets [Member]

Other intangible assets [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

$61,167,000

$58,766,000

$22,126,000

$22,126,000

'

'

$7,334,000

$7,334,000

'

'

$4,100,000

$4,100,000

'

'

$4,000,000

$4,000,000

'

'

$3,078,000

$3,152,000

$3,078,000

'

'

$2,513,000

$2,513,000

'

'

$3,000,000

$3,000,000

'

'

$5,354,000

$5,354,000

'

'

$3,000,000

$1,500,000

'

'

$1,250,000

$1,250,000

'

'

$1,011,000

$1,011,000

'

'

$500,000

$500,000

'

'

$700,000

$700,000

'

'

$1,500,000

$625,000

'

'

$1,701,000

$1,601,000

'

'

Accumulated Amortization

($21,188,000)

($17,879,000)

($6,474,000)

($4,980,000)

'

'

($2,917,000)

($2,554,000)

'

'

($1,503,000)

($1,298,000)

'

'

($1,400,000)

($1,200,000)

'

'

($1,258,000)

($1,028,000)

'

'

'

($390,000)

($260,000)

'

'

($1,032,000)

($844,000)

'

'

($3,962,000)

($3,757,000)

'

'

'

'

'

'

($62,000)

'

'

'

($519,000)

($460,000)

'

'

'

'

'

'

($403,000)

($368,000)

'

'

($75,000)

'

'

'

($1,193,000)

($1,130,000)

'

'

Amortization Period

'

'

'

'

'5 years

'10 years

'

'

'

'10 years

'

'

'

'10 years

'

'

'

'10 years

'

'

'

'3 years

'10 years

'

'

'

'10 years

'

'

'

'10 years

'

'

'3 years

'11 years 6 months

'

'

'

'10 years

'

'

'

'10 years

'

'

'3 years

'10 years

'

'

'

'10 years

'

'

'

'10 years

'

'

'

'10 years

'

'

'5 years

'10 years

Intangible_Assets_Components_o1

Intangible Assets - Components of Net Intangible Assets (Parenthetical) (Detail) (ECR intangible assets [Member], USD $)	Oct. 31, 2013	Apr. 30, 2013
ECR intangible assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Goodwill	$545,000	$545,000

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Oct. 31, 2012

Apr. 30, 2013

Aug. 31, 2012

Jul. 31, 2011

Jun. 28, 2011

Oct. 31, 2013

Apr. 30, 2013

Mar. 31, 2013

Apr. 30, 2012

Mar. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Jul. 29, 2011

Jul. 29, 2011

Jul. 29, 2011

Nov. 28, 2011

Jul. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Nov. 29, 2011

Feb. 28, 2013

Oct. 31, 2013

Apr. 30, 2013

Jul. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Dec. 31, 2012

Jan. 31, 2011

Oct. 31, 2013

Apr. 30, 2013

Aug. 19, 2011

Mar. 07, 2012

Oct. 31, 2013

Apr. 30, 2013

Nov. 19, 2013

Atley Pharmaceuticals intangible assets [Member]

Atley Pharmaceuticals intangible assets [Member]

Atley Pharmaceuticals intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan and Zolvit intangible assets [Member]

Orbivan [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

KVK License intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Flunisolide intangible assets [Member]

Partnered ANDA intangible assets [Member]

Partnered ANDA intangible assets [Member]

Partnered ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

In-licensed ANDA intangible assets [Member]

TussiCaps intangible assets [Member]

TussiCaps intangible assets [Member]

TussiCaps intangible assets [Member]

TussiCaps intangible assets [Member]

Sinus Buster intangible assets [Member]

Sinus Buster intangible assets [Member]

Sinus Buster intangible assets [Member]

Sinus Buster intangible assets [Member]

Payment

Dexbrompheniramine maleate [Member]

Pseudoephedrine sulfate [Member]

Patents

Subsequent Event [Member]

Milligram

Milligram

Hi-Tech [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense of intangible assets

$1,651,000

$1,761,000

$3,309,000

$3,518,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid for acquiring marketing and distribution rights

'

'

'

'

'

'

'

3,220,000

'

100,000

'

200,000

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,600,000

1,344,000

'

'

'

Inventory acquired, value

'

'

'

'

'

'

'

298,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82,000

'

'

'

Additional amount paid for acquiring rights

'

'

'

'

'

291,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,750,000

'

'

'

'

Prepaid royalties

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite lived intangible assets divested

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of payments for divested asset

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets value

61,167,000

'

61,167,000

'

58,766,000

'

'

'

3,078,000

3,152,000

3,078,000

'

'

1,250,000

1,250,000

'

'

'

'

'

1,500,000

625,000

'

'

500,000

500,000

'

3,000,000

1,500,000

'

'

22,126,000

22,126,000

'

'

2,513,000

2,513,000

'

Extended release tablets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

120

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Refunds received

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired finite lived intangible purchase price quarterly repayment amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,750,000

'

'

'

'

'

'

Period of additional payment for acquiring rights

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payment liability amounted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,445,000

'

11,993,000

'

'

'

'

Adjustment of preliminary contingent liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,189,000

'

'

'

'

'

'

'

Current liability

56,429,000

'

56,429,000

'

43,896,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,875,000

'

'

'

'

'

'

Number of patents used to cover product

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

TussiCaps is covered by a patent expires period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'September 2024

'

'

'

'

'

'

Patent two expiry period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'January 2025

'

'

'

'

'

'

Purchase price and interest in intellectual property

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price and interest payable in installments period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'24 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company and the other party will each own the product and will each pay equal amounts in satisfaction of the purchase price obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The other party will also pay the development costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The other party will also share the net profits

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional payment related to asset purchase agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payment for product acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

875,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additions to Intangibles

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deposited in escrow

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

Balance of escrow account distributed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

767,000

Royalty payment condition for company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Hi-Tech will also pay a royalty on net sales for 3 1/2 years, or a maximum of $1,750,000, whichever is reached first

'

'

'

Royalty on net sales, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 7 months 6 days

'

'

'

Royalty on net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,750,000

'

'

'

Acquiring marketing and distribution rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

Milestone liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

Amount payable on completion of milestone

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

Monthly payment if sale target achieved

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

Marketing and distribution rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)	6 Months Ended
	Oct. 31, 2013	Jun. 01, 2010	Oct. 13, 2011	Jun. 15, 2010	Jun. 01, 2010
	Revolving Credit Agreement [Member]	Revolving Credit Agreement [Member]	Equipment financing agreement [Member]	Equipment financing agreement [Member]	Equipment financing agreement [Member]
Debt Disclosure [Abstract]	'	'	'	'	'
Maximum borrowing capacity pursuant to revolving credit note	'	$10,000,000	'	'	$5,000,000
Revolving credit facility interest rate description	'CB Floating Rate shall never be less than the Adjusted One Month LIBOR Rate, or for a LIBOR Loan, at a rate equal to the Adjusted LIBOR Rate plus the Applicable Margin	'	'	'	'
Borrowings under revolving credit agreement	0	'	'	'	'
Revolving Credit Agreement expired date	27-May-13	'	'	'	'
Borrowings under equipment financing agreement	'	'	'	621,000	'
Additional borrowings under financing agreement	'	'	$1,155,000	'	'

Freight_Expense_Additional_Inf

Freight Expense - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Freight Expense [Abstract]	'	'	'	'
Amount of outgoing freight costs (included in selling, general, and administrative expense)	$1,492,000	$1,477,000	$2,780,000	$2,785,000

Stockholders_Equity_Additional

Stockholder's Equity - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

Dec. 28, 2012

Jul. 31, 2012

Oct. 31, 2013

Nov. 30, 2012

Oct. 31, 2013

Oct. 31, 2013

Oct. 07, 2013

Jan. 09, 2013

Oct. 31, 2013

Oct. 31, 2012

22-May-13

Oct. 31, 2013

Aug. 02, 2012

Jul. 16, 2012

2009 Stock Option Plan [Member]

1994 Directors Stock Option Plan [Member]

2012 Incentive Compensation Plan [Member]

2012 Incentive Compensation Plan [Member]

2012 Incentive Compensation Plan [Member]

2012 Incentive Compensation Plan [Member]

Employee Stock Option Plan [Member]

Employee Stock Option Plan [Member]

Employee Stock Option Plan [Member]

Employees And Directors Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefit With incentive stock options

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

Contractual term of stock options granted

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Vesting period of stock options granted

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

Weighted average forfeiture rate

'

'

9.00%

'

'

'

'

'

'

'

'

'

'

'

Number of options granted

'

'

'

'

'

'

'

'

'

'

40,000

'

2,500

442,000

Exercise price of options granted

'

$33

'

'

'

'

'

'

'

'

$33.81

'

'

$32.59

Options Grants

'

'

'

'

0

0

'

'

'

'

'

40,000

'

'

Closing stock price

'

'

$43.09

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options exercised

'

'

'

'

'

'

'

'

7,301,000

4,538,000

'

'

'

'

Total unrecognized compensation cost related to stock options

'

'

'

'

'

'

'

'

10,312,000

'

'

'

'

'

Weighted average period for recognition of compensation cost related to stock options

'

'

'

'

'

'

'

'

'2 years 8 months 12 days

'

'

'

'

'

Number of common stock received

'

'

'

'

'

'

26,000

35,000

'

'

'

'

'

'

Number of exercise stock option

'

'

'

'

'

'

75,000

112,500

'

'

'

220,000

'

'

Payment of stock option exercise

'

'

'

'

'

'

1,124,000

1,301,000

'

'

'

'

'

'

Treasury stock

'

'

'

'

'

'

26,000

35,000

'

'

'

'

'

'

Special one-time dividend declared

'

'

'

$1.50

'

'

'

'

'

'

'

'

'

'

Cash payment in connection with dividend

$20,176,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend declare date

'

'

30-Nov-12

'

'

'

'

'

'

'

'

'

'

'

Dividend payment date

'

'

28-Dec-12

'

'

'

'

'

'

'

'

'

'

'

Dividend record date

'

'

13-Dec-12

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Stockbased

Stockholder's Equity - Stock-based Compensation Expense before Income Tax Benefit (Detail) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$1,353,000	$1,041,000	$2,695,000	$1,826,000
Cost of goods sold [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	141,000	125,000	282,000	217,000
Selling, general and administrative expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	957,000	735,000	1,914,000	1,271,000
Research and product development costs [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$255,000	$181,000	$499,000	$338,000

Stockholders_Equity_Weighted_A

Stockholder's Equity - Weighted Average Assumptions Used for Stock Options Granted (Detail) (USD $)	0 Months Ended	1 Months Ended
	Aug. 02, 2012	22-May-13	Jul. 16, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Expected volatility	54.00%	53.00%	54.00%
Risk-free interest rate	0.60%	0.91%	0.60%
Expected term	'4 years	'4 years	'4 years
Expected dividend yield	0.00%	0.00%	0.00%
Weighted average fair value per share at grant date	$13.79	$13.92	$13.62

Stockholders_Equity_Summary_of

Stockholder's Equity - Summary of Stock Option Activity and Related Information for Stock Option Plan (Detail) (USD $)	6 Months Ended
	Oct. 31, 2013
Employee Stock Option Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, Outstanding, Beginning balance	1,987,000
Shares, Grants	40,000
Shares, Exercised	-220,000
Shares, Forfeitures or expirations	-22,000
Shares, Outstanding, Ending balance	1,785,000
Shares, Vested and expected to vest	1,688,000
Shares, Exercisable	705,000
Weighted-Average Exercise Price Outstanding, Beginning balance	$24.03
Weighted-Average Exercise Price, Grants	$33.81
Weighted-Average Exercise Price, Exercised	$17.74
Weighted-Average Exercise Price, Forfeitures or expirations	$28.62
Weighted-Average Exercise Price Outstanding, Ending balance	$24.95
Weighted-Average Exercise Price, Vested and expected to vest	$24.68
Weighted-Average Exercise Price, Exercisable	$17.78
Weighted-Average Remaining Contractual Term, Outstanding	'7 years
Weighted-Average Remaining Contractual Term, Vested and expected to vest	'6 years 10 months 24 days
Weighted-Average Remaining Contractual Term, Exercisable	'5 years
Aggregate Intrinsic Value, Outstanding	$32,377,000
Aggregate Intrinsic Value, Vested and expected to vest	31,312,000
Aggregate Intrinsic Value, Exercisable	19,051,000
Directors Stock Option Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, Outstanding, Beginning balance	446,000
Shares, Grants	'
Shares, Exercised	-71,000
Shares, Forfeitures or expirations	'
Shares, Outstanding, Ending balance	375,000
Shares, Vested and expected to vest	375,000
Shares, Exercisable	250,000
Weighted-Average Exercise Price Outstanding, Beginning balance	$19.64
Weighted-Average Exercise Price, Grants	'
Weighted-Average Exercise Price, Exercised	$16.98
Weighted-Average Exercise Price, Forfeitures or expirations	'
Weighted-Average Exercise Price Outstanding, Ending balance	$20.15
Weighted-Average Exercise Price, Vested and expected to vest	$20.15
Weighted-Average Exercise Price, Exercisable	$15.74
Weighted-Average Remaining Contractual Term, Outstanding	'5 years 6 months
Weighted-Average Remaining Contractual Term, Vested and expected to vest	'5 years 6 months
Weighted-Average Remaining Contractual Term, Exercisable	'4 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	8,608,000
Aggregate Intrinsic Value, Vested and expected to vest	8,608,000
Aggregate Intrinsic Value, Exercisable	$7,083,000

Product_Divestitures_Additiona

Product Divestitures - Additional Information (Detail) (USD $)	0 Months Ended	6 Months Ended
	31-May-11	Oct. 31, 2013	Oct. 31, 2012	Apr. 30, 2011	Jul. 03, 2009
Discontinued Operations And Disposal Groups [Abstract]	'	'	'	'	'
Amount received in exchange for marketing rights	'	'	'	'	$1,000,000
Maximum annual royalty receivable on sales of products	'	1,500,000	'	'	'
Royalty earned under the agreement	'	0	54,000	'	'
Cash received on divestiture	1,700,000	'	'	'	'
Impairment charge on divestiture	'	'	'	1,300,000	'
Net gain (loss) on divestiture	$0	'	'	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	6 Months Ended
	Oct. 31, 2013	Apr. 30, 2013
Income Tax Disclosure [Abstract]	'	'
Estimated effective tax rate	34.00%	'
Liability for uncertain tax positions current	$0	$0

Contingencies_and_Other_Matter1

Contingencies and Other Matters - Additional Information (Detail) (USD $)

1 Months Ended

Feb. 09, 2010

Oct. 31, 2013

Apr. 30, 2013

Jun. 08, 2012

Oct. 31, 2013

Jan. 08, 2013

16-May-12

Mar. 13, 2012

Aug. 17, 2011

Jan. 27, 2012

Oct. 31, 2011

Oct. 11, 2011

Defendant

sqft

Scenario, Forecast [Member]

Bimatoprost Topical [Member]

Bimatoprost Topical [Member]

Bimatoprost Topical [Member]

Bimatoprost Topical [Member]

Allergan's Lumigan [Member]

Allergan's Zymar gatifloxacin ophthalmic solution [Member]

Allergan's Zymaxid gatifloxacin ophthalmic solution [Member]

Contingencies And Other Matters [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Loss contingency loss reserve for administrative relating default

'

'

$15,500,000

$700,000

$25,000,000

'

'

'

'

'

'

'

Percentage of solutions

'

'

'

'

'

0.03%

0.03%

0.03%

0.03%

0.01%

0.30%

0.50%

Number of named defendants

68

'

'

'

'

'

'

'

'

'

'

'

Area available under leasing

'

12,000

'

'

'

'

'

'

'

'

'

'

Amount payable on the lease agreement in current year

'

90,000

'

'

'

'

'

'

'

'

'

'

Amount payable on the lease agreement in year two

'

90,000

'

'

'

'

'

'

'

'

'

'

Amount payable on the lease agreement in year three

'

90,000

'

'

'

'

'

'

'

'

'

'

Amount payable on the lease agreement in year four

'

90,000

'

'

'

'

'

'

'

'

'

'

Amount payable on the lease agreement in year five

'

90,000

'

'

'

'

'

'

'

'

'

'

Minimum purchase price of manufacturing agreement in first year

'

500,000

'

'

'

'

'

'

'

'

'

'

Minimum purchase price of manufacturing agreement in second year

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Minimum purchase price of manufacturing agreement in third year

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Minimum purchase price of manufacturing agreement in fourth year

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Minimum purchase price of manufacturing agreement in fifth year

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

Significant_Customers_and_Conc2

Significant Customers and Concentration of Credit Risk - Percentages of Net Sales and Gross Trade Accounts Receivable Attributed to Each Customer (Detail)	6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Net Sales [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	64.00%	65.00%
Net Sales [Member] | AmerisourceBergen Corporation [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	17.00%	14.00%
Net Sales [Member] | Cardinal Health, Inc. [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	12.00%	13.00%
Net Sales [Member] | McKesson Corporation [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	16.00%	21.00%
Net Sales [Member] | Walgreens [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	19.00%	17.00%
Gross Accounts Receivable [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	67.00%	67.00%
Gross Accounts Receivable [Member] | AmerisourceBergen Corporation [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	17.00%	15.00%
Gross Accounts Receivable [Member] | Cardinal Health, Inc. [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	14.00%	13.00%
Gross Accounts Receivable [Member] | McKesson Corporation [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	24.00%	25.00%
Gross Accounts Receivable [Member] | Walgreens [Member]	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'
Concentration of credit risk	12.00%	14.00%

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Financial Liabilities Subject to Fair Value Measurements (Detail) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Schedule of Financial Liabilities Subject to Fair Value Measurements [Abstract]	'	'
Contingent payment liability, Fair value	$6,445,000	$7,719,000
Contingent payment liability, Level 3	$6,445,000	$7,719,000

Fair_Value_Measurements_Roll_F

Fair Value Measurements - Roll Forward of Contingent Payment Liability (Detail) (USD $)	6 Months Ended
	Oct. 31, 2013
Roll Forward of Contingent Payment Liability [Abstract]	'
Contingent payment liability, Beginning balance	$7,719,000
Payments on contingent liability	-1,438,000
Interest expense	164,000
Contingent payment liability, Ending balance	$6,445,000

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail)	6 Months Ended
	Oct. 31, 2013
Fair Value Disclosures [Abstract]	'
Discount rate used in computation of present value of contingent liability	5.20%

Segment_Information_Additional

Segment Information - Additional Information (Detail)	6 Months Ended
	Oct. 31, 2013
	Segment
Segment Reporting [Abstract]	'
Reportable business segments	3

Segment_Information_Operating_

Segment Information - Operating Income from Reportable Business Segments before Income Taxes (Detail) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'
NET SALES	$58,601,000	$57,537,000	$109,102,000	$109,580,000
Cost of goods sold	27,291,000	27,948,000	52,367,000	54,670,000
Gross profit	31,310,000	29,589,000	56,735,000	54,910,000
Amortization expense	-1,651,000	-1,761,000	-3,309,000	-3,518,000
Income (loss) before income taxes	1,775,000	13,111,000	8,665,000	22,097,000
Hi-Tech [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
NET SALES	47,732,000	47,286,000	91,261,000	93,208,000
Cost of goods sold	24,241,000	24,434,000	47,084,000	49,158,000
Gross profit	23,491,000	22,852,000	44,177,000	44,050,000
Amortization expense	-209,000	-278,000	-419,000	-591,000
Income (loss) before income taxes	16,241,000	17,371,000	30,810,000	32,185,000
HCP [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
NET SALES	4,100,000	4,658,000	7,583,000	7,684,000
Cost of goods sold	1,576,000	1,984,000	3,004,000	3,324,000
Gross profit	2,524,000	2,674,000	4,579,000	4,360,000
Amortization expense	-270,000	-304,000	-540,000	-574,000
Income (loss) before income taxes	976,000	-3,000	805,000	-746,000
ECR [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
NET SALES	6,769,000	5,593,000	10,258,000	8,688,000
Cost of goods sold	1,474,000	1,530,000	2,279,000	2,188,000
Gross profit	5,295,000	4,063,000	7,979,000	6,500,000
Amortization expense	-1,172,000	-1,179,000	-2,350,000	-2,353,000
Income (loss) before income taxes	257,000	-134,000	-2,382,000	-1,931,000
Corporate and Other [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
NET SALES	'	'	'	'
Cost of goods sold	'	'	'	'
Gross profit	'	'	'	'
Amortization expense	'	'	'	'
Income (loss) before income taxes	($15,699,000)	($4,123,000)	($20,568,000)	($7,411,000)